Shots:
- Myriad Genetics to launch the Prolaris + AI Test, with the new AI metric available for all Prolaris Biopsy Tests in the US from May 29, 2026 excl. New York; approval in NY is expected soon
- A validation study of 998 pts for model training & 296 pts for validation, demonstrated that AI-GUR independently predicted Gleason score upgrades at first follow-up biopsy in pts with Gleason 3+3 & 3+4 prostate cancer, identifying risk insights beyond conventional risk stratification tools & cribriform morphology
- Prolaris + AI Test integrates long-term prognostic insights from the Prolaris clinical CCR score with near-term risk from the AI-GUR (Gleason Upgrade Risk) model to help guide active surveillance selection & personalize monitoring intensity in prostate cancer
Ref: Globenewswire | Image: Myriad Genetics | Press Release
Related News: Myriad Genetics Receives the US FDA Approval for MyChoice CDx Test as a Companion Diagnostic for GSK’s Zejula
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
